National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

被引：0
|
作者：
Dursun, A. [1 ]
Bavbek, S. [2 ]
Misirligil, Z. [2 ]
Erdener, F. [3 ]
Buyukozturk, S. [4 ]
Aydin, O. [2 ]
Gemicioglu, B. [5 ]
Bayrak, P. [6 ]
Erkekol, Oner F. [1 ]
Yildirim, Z. [7 ]
Cilli, A. [8 ]
Boz, Bingol A. [9 ]
Alpaydyn, Ozgen A. [10 ]
Karakoc, G. [11 ]
Gorguner, M. [12 ]
Karakaya, G. [13 ]
Isik, R. [14 ]
Sapan, N. [15 ]
Bakirtas, A. [16 ]
机构：
[1] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Allergy Clin, Ankara, Turkey
[2] Ankara Univ, Sch Med, Dept Resp Med, Div Clin Immunol & Allergy, TR-06100 Ankara, Turkey
[3] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Med Sch, Dept Internal Med, Div Allerg Dis, Istanbul, Turkey
[5] Istanbul Univ, Cerrahpasa Med Sch, Dept Resp Med, Istanbul, Turkey
[6] Celal Bayar Univ, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Manisa, Turkey
[7] Fatih Univ, Sch Med, Dept Resp Med, Ankara, Turkey
[8] Akdeniz Univ, Sch Med, Dept Resp Med, TR-07058 Antalya, Turkey
[9] Akdeniz Univ, Sch Med, Dept Pediat, Div Allergy, TR-07058 Antalya, Turkey
[10] Celal Bayar Univ, Sch Med, Dept Resp Med, Manisa, Turkey
[11] Cukurova Univ, Sch Med, Dept Pediat, Div Allergy, Adana, Turkey
[12] Ataturk Univ, Sch Med, Dept Resp Med, Erzurum, Turkey
[13] Hacettepe Univ, Sch Med, Dept Resp Med, Adult Allergy Unit, Ankara, Turkey
[14] Seyhan Training & Res Hosp, Adult Allergy Unit, Adana, Turkey
[15] Uludag Univ, Sch Med, Dept Pediat, Div Allergy, Bursa, Turkey
[16] Gazi Univ, Sch Med, Dept Pediat, Div Allergy, Ankara, Turkey
来源：
ALLERGY | 2011年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1786
引用
收藏
页码：675 / 676
页数：2
相关论文
共 50 条
  • [31] Omalizumab in Patients with Severe Asthma and Persistent Sputum Eosinophilia
    Mukherjee, Manali
    Kjarsgaard, Melanie
    Radford, Katherine
    Huang, Chynna
    Leigh, Richard
    Dorscheid, Del
    Lemiere, Catherine
    Boulet, Louis-Philippe
    Waserman, Susan
    Martin, James G.
    Nair, Parameswaran K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB434 - AB434
  • [32] Omalizumab in patients with severe asthma and persistent sputum eosinophilia
    Manali Mukherjee
    Melanie Kjarsgaard
    Katherine Radford
    Chynna Huang
    Richard Leigh
    Delbert R. Dorscheid
    Catherine Lemiere
    Louis-Philippe Boulet
    Susan Waserman
    James Martin
    Parameswaran Nair
    Allergy, Asthma & Clinical Immunology, 15
  • [33] Dupilumab-related eosinophilia in patients with severe asthma: Post-marketing surveillance in Japan
    Nagata, Makoto
    Yamaguchi, Ryo
    Usami, Makiko
    Orimo, Mami
    Ishida, Masato
    ALLERGOLOGY INTERNATIONAL, 2025, 74 (01) : 169 - 171
  • [34] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    Ohashi, Satoshi
    Koga, Tadashi
    Toyoda, Tetsumi
    Ishii, Mika
    DRUGS-REAL WORLD OUTCOMES, 2019, 6 (01) : 27 - 35
  • [35] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Yukinori Sakata
    Toshiyuki Matsuoka
    Satoshi Ohashi
    Tadashi Koga
    Tetsumi Toyoda
    Mika Ishii
    Drugs - Real World Outcomes, 2019, 6 : 27 - 35
  • [36] Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout.
    Bahrt, Kenneth M.
    Yeo, Anthony E.
    Howson, Tina L.
    Ottery, Faith D.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S73 - S74
  • [37] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] OMALIZUMAB REDUCES MAINTENANCE ORAL CORTICOSTEROID USE IN PATIENTS WITH SEVERE PERSISTENT ALLERGIC ASTHMA
    Niven, R.
    Molimard, M.
    Buhl, R.
    Le Gros, V.
    Thielen, A.
    Thirlwell, J.
    Maykut, R.
    THORAX, 2009, 64 : A130 - A130
  • [39] Post-marketing Safety Experience with Vedolizumab: Malignancy
    Bhayat, Fatima
    Blake, Aimee
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S313 - S314
  • [40] Therapy with omalizumab in patients with severe persistant allergic asthma: real life data in Turkey
    Bavbek, S.
    Aydin, O.
    Ozdemir, Kepil S.
    Yilmaz, I
    Celik, G.
    Demirel, Y.
    Mungan, D.
    Sin, B.
    Kursun, N.
    Misirligil, Z.
    ALLERGY, 2011, 66 : 366 - 366
12345